

FORMULATION OF AN ANTI-TUBERCULOSIS DRUG DELIVERY SYSTEM

LISA CLAIRE DU TOIT



A dissertation submitted to the Faculty of Health Sciences, University of the Witwatersrand,
in fulfillment of the requirements for the degree of Master of Pharmacy

Supervisor:

Professor Michael Paul Danckwerts
Department of Pharmacy and Pharmacology, University of the Witwatersrand, South Africa

Co-Supervisor:

Professor Viness Pillay
Department of Pharmacy and Pharmacology, University of the Witwatersrand, South Africa

Johannesburg, 2007

DECLARATION

I, Lisa Claire du Toit, declare that this dissertation is my own work. It has being submitted for the degree of Master of Pharmacy in the Faculty of Health Sciences in the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at this or any other University.

.....
This day of February 2007

RESEARCH OUTPUTS

1. Research Publications

- a. Lisa Claire du Toit, Viness Pillay and Michael Paul Danckwerts. Application of Synergism and Variation in Ionic Compatibilities within a Hydrophilic Polymeric Sodium Starch Glycolate- κ -Carrageenan Combination: Textural Profiling of the Suspension Behavior. *Journal of Bioactive and Compatible Polymers*. 2006, 21: 107-122.
- b. Lisa Claire du Toit, Viness Pillay and Michael Paul Danckwerts. Tuberculosis Chemotherapy: Current Drug Delivery Approaches. *Respiratory Research*. 2006, 7: 118.

2. Conference Outputs

- a. Lisa Claire du Toit, Michael Paul Danckwerts and Viness Pillay. Formulation of an Anti-Tuberculosis Drug Delivery System: Microencapsulation of Isoniazid. Young Scientist Competition Abstract Entrant Presented at 26th Annual Conference of the Academy of Pharmaceutical Sciences, 29 September – 2 October 2005, Port Elizabeth.
- b. Lisa Claire du Toit, Michael Paul Danckwerts and Viness Pillay. A Novel Salting-Out Approach for the Formulation of Cross-linked Enterospheres Incorporating Isoniazid. Poster Presented at 33rd Annual Meeting & Exposition of the Controlled Release Society, 22-26 July 2006, Vienna, Austria.
- c. Lisa Claire du Toit, Viness Pillay and Michael Paul Danckwerts. Textural Characterization of Synergism in Hydrophilic Polymeric Sodium Starch Glycolate- κ -Carrageenan Sol and Gel Systems. Poster Presented at 33rd Annual Meeting & Exposition of the Controlled Release Society, 22-26 July 2006, Vienna, Austria.

- d. Lisa Claire du Toit, Michael Paul Danckwerts and Viness Pillay. Formulation of an Anti-Tuberculosis Site-Specific Drug Delivery System: A Comparative Study of Two Methods for Enteric-Coating Isoniazid Particles. Poster Presented at 26th Annual Conference of the Academy of Pharmaceutical Sciences, 29 September – 2 October 2005, Port Elizabeth.
- e. Lisa Claire du Toit, Michael Paul Danckwerts and Viness Pillay. Evaluation of Novelty-Formed Nano- and Entero-spheres for Targeted Delivery of an Anti-Tuberculosis Drug. Podium Presentation at ICPPS Conference 2006, Vanderbijlpark, South Africa.
- f. Lisa Claire du Toit, Viness Pillay, Michael Paul Danckwerts, Craig Cremen, Ismail Ravat, Jayendran Subramoney and Harshen Vassan. Approaches to Fabricating Anti-TB Nanosystems Embodying a Salted-Out and Cross-linked Architecture. Poster Presented at ICPPS Conference 2006, Vanderbijlpark, South Africa.
- g. Lisa Claire du Toit, Viness Pillay, Michael Paul Danckwerts, Craig Cremen, Ismail Ravat, Jayendran Subramoney and Harshen Vassan. Preliminary production of enteronanoparticles based on a salted-out and cross-linked architecture. Poster Presented at the American Association of Pharmaceutical Scientists Annual Meeting and Exposition Conference, October 2006, Texas, USA.

3. Additional Research Outputs

- a. Lisa Claire du Toit, Oluwutoyin Kolawole, Viness Pillay and Michael Paul Danckwerts. The Wits Approach: A Bioactive Research Network (Article), South African Pharmacy Journal, October 2005.
- b. Lisa Claire du Toit, Michael Paul Danckwerts and Viness Pillay. Formulation of an Anti-Tuberculosis Site-Specific Drug Delivery System. Podium Presentation at School

of Therapeutic Sciences Research Afternoons, University of the Witwatersrand, 10-11 August 2005.

- c. Lisa Claire du Toit, Michael Paul Danckwerts and Viness Pillay. Formulation of an Anti-Tuberculosis Site-Specific Drug Delivery System: A Comparative Study of Two Methods for Enteric-Coating Isoniazid Particles. Podium Presentation at Faculty Research Day, University of the Witwatersrand, 23 August 2006.
- d. Lisa Claire du Toit, Michael Paul Danckwerts and Viness Pillay. Formulation of an Anti-Tuberculosis Drug Delivery System. Podium Presentation at the 1st Symposium for Biomaterials Science and Applications, University of the Witwatersrand, 4 September 2006.

ABSTRACT

Tuberculosis (TB) is a leading killer of young adults worldwide and the global scourge of multi-drug resistant tuberculosis is reaching epidemic proportions. A number of novel drug delivery systems incorporating the principle anti-tuberculosis (anti-TB) agents have been fabricated that either target the site of TB infection or reduce the dosing frequency with the aim of improving patient outcomes; however, there is a requisite to manufacture an oral system, which directly addresses issues of unacceptable rifampicin (RIF) bioavailability recently reported in a number of fixed-dose combinations (FDCs). There is an urgent need to segregate the delivery of RIF and isoniazid (INH) upon co-administration, such that INH is not released in the stomach owing to the induction of accelerated hydrolysis of RIF in acidic medium to the poorly absorbed insoluble 3-formyl rifamycin SV in the presence of INH. The fabrication of a polymeric once-daily oral multiparticulate fixed-dose combination of the principal anti-TB drugs, which attains segregated delivery of RIF and INH for improved RIF bioavailability, could be a step in the right direction in addressing issues of treatment failure due to administration of poor quality FDCs and patient non-compliance.

Novel approaches were implemented for the fabrication of an oral multiparticulate system for differentiated release of RIF and INH in the gastrointestinal tract. The envisaged system comprised INH-loaded enterosoluble multiparticulate entities for targeted delivery of the INH to the small intestine and reconstitutable multiparticulate entities incorporating the poorly water-soluble RIF and appropriate gel-forming hydrophilic suspending agents, which were required to disintegrate rapidly in tepid water to form a gel network suspending RIF and the INH-loaded enterosoluble multiparticulates. The dry dispersible multiparticulate system may be reconstituted immediately prior to administration to the patient for once-daily dosing as a compliance-promoting tool.

The design of a novel anti-TB drug delivery system hinged on preformulatory investigations and preliminary experimental activities to yield a sufficient database to allow for the selection of the qualitative composition of a prototype formulation. The aforementioned activities initiated the systematic identification of an innovative method for formulating enterosoluble multiparticulates demonstrating the required enteric-release properties. The novelty-formed multiparticulates, referred to as 'enterospheres', were obtained by inducing separation ('salting-out') of a pH-sensitive poly (methacrylic acid-co-ethylacrylate) copolymer as a polymer-rich enteric film and ionotropically cross-linking the internal enterosphere matrix. Rational selection of appropriate suspending agents for design of reconstitutable multiparticulates resolved in the identification of a synergistic hydrophilic sodium starch glycolate-kappa carrageenan combination, duly characterised by physicochemical analyses. The gel-forming composite system attained ease of dispersal and the formation of a three-dimensional supporting network possessing the essential properties for extemporaneous use.

Statistical experimental design, implementing response surface methodology, was pivotally instituted on the multiparticulate forms for the identification of critical formulation and processing variables for the development of the optimum enterosoluble and reconstitutable multiparticulate systems for delivery to the patient as the preferred multiparticulate two-drug FDC. Because there was an unequivocal relationship between the properties of a cross-linked enterospheres and their structure in such a way that both characteristics could not be considered in an isolated way, in-depth analyses on drug-free and drug-loaded enterospheres was systematically undertaken.

Of principle concern in this study was the attainment of segregated gastrointestinal delivery of RIF and INH in order to address issues of unacceptable RIF bioavailability on co-administration with INH. The proposed United States Pharmacopoeial (USP) high performance liquid chromatographic (HPLC) and colorimetric method, and a proposed regression analysis of ultraviolet (UV) spectrophotometric absorbance data were employed to resolve RIF and INH release from the optimum multiparticulate system at simulated gastric pH for comparison with the release profiles of anti-TB FDCs commercially available in South Africa.

Ultimately, in keeping up to speed with future trends, this dissertation addressed innovations in nanotechnology, with particular reference to anti-TB nanosystems. The novelty identified method for enterosphere manufacture was adapted with a view to nanosizing the salted-out and cross-linked architecture, for controlled delivery of anti-TB drugs to the patient, in the bid to promote patient adherence.

ACKNOWLEDEMENTS

In completing this work, the author would like to express her deepest gratitude to all who have offered their much-needed aid and support towards the completion of this study. The author would like to acknowledge the following people for their great contribution:

- Foremost to my parents, sister and grandparents for their endearing love and support, and for lifting my spirits when times were tough.
- To my supervisor, Prof. Michael Paul Danckwerts, for his knowledge and encouragement.
- To my co-supervisor, Prof. Viness Pillay, for his inspiring commitment to the field; thirst for knowledge, which is permeating; and for his constant support.
- To the students and staff of the Department of Pharmacy and Pharmacology, University of the Witwatersrand: their contributions, great and small, have aided me in numerous ways.
- To Dr. Clem Penny, for his advisory support with the scanning electron microscopy.
- This research would also not have been possible without the financial assistance of the Medical Research Council (MRC) and the National Research Foundation (NRF) of South Africa, their support is greatly appreciated.
- To the Almighty Father, without Whom none of this would be possible.

DEDICATION

This work is dedicated to my nephew, Liam Matthew du Toit, an unexpected, yet most wonderful gift.

This dissertation is also dedicated to my country, South Africa.

TABLE OF CONTENTS

	Page
1. Introduction	
1.1. Tuberculosis – Delineating the Disease	1
1.2. Current Anti-tuberculosis Chemotherapy	5
1.3. Novel Drug Delivery Systems for the Treatment of TB	13
1.4. Statement of the Problem	19
1.5. Approach to the Problem	23
1.6. Aims and Objectives: Description of the Oral Multiparticulate Drug Delivery System	27
1.7. Overview of the Dissertation	32
2. Theoretical Considerations for the Design of a Dispersible System Incorporating the Enterosoluble and Dispersible Multiparticulate Entities	
2.1. Introduction	36
2.2. Site-Specific Drug Delivery of Multiparticulate Dosage Forms	37
2.3. Selection of an Appropriate Enteric Polymer	39
2.4. Gastrointestinal Anatomy and Physiology Relative to Enteric-Coating Functioning and Design Rationale	45
2.4.1. The Significance of pH	46
2.4.2. Gastric Motility, Emptying and Residence Time	47
2.4.3. Considerations for Drug Release Testing and Development of an Isoniazid Assay Method	50

2.5.	Theoretical Design of an Enterosoluble Multiparticulate System	51
2.5.1.	Microencapsulation Technology	51
2.5.2.	Fabrication of Enterosoluble Multiparticulates by the Air Suspension Method	52
2.5.3.	Fabrication of Enterosoluble Multiparticulates by Solvent Evaporation Emulsification	55
2.5.4.	Fabrication of Enterosoluble Multiparticulates Employing the Principles of Phase Separation ('Salting-Out')	56
2.6.	Delivery of the Enterosoluble Multiparticulates	57
2.6.1.	Rationalising Dispersible Multiparticulates as a Dosage Form	57
2.6.2.	Ability of a Suspending Agent to Form an Extemporaneous Gel in Tepid Water: Formulation Considerations	58
2.7.	Concluding Remarks	62
3.	Preliminary Design of an Enterosoluble Multiparticulate System Incorporating Isoniazid	
3.1.	Introduction	63
3.2.	Development of a Methodology for the Fabrication of Entero granules by the Air Suspension Method	64
3.2.1.	Materials and Methods	64
3.2.1.1.	Materials	64
3.2.1.2.	Equipment	64
3.2.1.3.	Identification of Processing Conditions for Successful Operation	65
3.2.1.3.1.	Control of Airflow	65

3.2.1.3.2. Fluid Application Rate	66
3.2.1.3.3. Drying Time and Temperature	66
3.2.1.4. Formulation of Enterogranules	66
3.2.1.5. Enteric-Film Coating of Enterogranules	67
3.2.1.6. Particle Size Analysis	69
3.2.1.7. Construction of Calibration Curves for Spectrophotometric Determination of Isoniazid Release from the Enterosoluble System	70
3.2.1.8. Drug Content of Enterogranules	71
3.2.1.9. <i>In Vitro</i> Release Studies on Enterogranules	71
3.2.2. Results and Discussion	72
3.3. Development of a Methodology for the Fabrication of Microenterospheres by the Polar Organic-in-Oil Emulsification Solvent Evaporation Method	77
3.3.1. Materials and Methods	77
3.3.1.1. Materials	77
3.3.1.2. Formulation of Microenterospheres	77
3.3.1.3. Microenterosphere Diameter Analysis	78
3.3.1.4. Encapsulation Efficiency of Microenterosphere	79
3.3.1.5. <i>In Vitro</i> Release Studies on Microenterospheres	79
3.3.2. Results and Discussion	80
3.4. Modifications to Overcome Burst Release from Microenterospheres	83
3.4.1. Materials and Methods	84
3.4.1.1. Materials	84
3.4.1.2. Double Entrapment of Methacrylic Acid Ethyl Acrylate Copolymer	85

3.4.1.3. Double Entrapment in Ethylcellulose	85
3.4.1.4. <i>In Vitro</i> Release Studies on Reservoir Systems	86
3.4.2. Results and Discussion	86
3.5. Development of a Methodology for the Fabrication of Enterospheres by Novel Salting-Out and Ionotropic Cross-linking of Methacrylic Acid Ethyl Acrylate	88
3.5.1. Materials and Methods	89
3.5.1.1. Materials	89
3.5.1.2. Formulation of Enterospheres	89
3.5.1.3. Enterosphere Diameter Analysis	93
3.5.1.4. Encapsulation Efficiency of Enterospheres	94
3.5.1.5. <i>In Vitro</i> Release Studies on Enterospheres	94
3.5.2. Results and Discussion	95
3.6. Treatment of Dissolution Data for Selection of a Candidate Enterosoluble System	101
3.6.1. Methodology	101
3.6.2. Results and Discussion	103
3.7. Concluding Remarks	105
4. Fabrication and Statistical Optimisation of Salted-Out and Internally Cross-linked Anti-Tuberculosis Polymeric Enterospheres Employing an Experimental Design Strategy	
4.1. Introduction	107

4.1.1. Development of an Experimental Design Strategy for Enterosphere	109
Fabrication and Optimisation	
4.2. Materials and Methods	112
4.2.1. Materials	112
4.2.2. Formulation of Enterospheres	112
4.2.3. Experimental Design	113
4.2.4. Surface Morphology and Shape Analysis of Enterospheres	114
4.2.5. Determination of Molar Amount of Zinc Incorporated within the Cross-linked Matrix	115
4.2.6. Drug Content and Entrapment Efficiency	115
4.2.7. <i>In Vitro</i> Drug Release Studies	116
4.2.8. Textural Profile Analysis	117
4.2.9. Optimisation of Formulation Ingredients	119
4.3. Results and Discussion	119
4.3.1. Surface Morphology of the Enterospheres	119
4.3.2. Measured Responses for the Experimentally-Synthesised Enterospheres	120
4.3.3. Analysis of the Box-Behnken Response Surface Design	127
4.3.4. Response Surface Analysis	132
4.3.4.1. Response Surface Analysis for Molar Amount of Zinc	132
4.3.4.2. Response Surface Analysis for Drug Entrapment Efficiency	136
4.3.4.3. Response Surface Analysis for Mean Dissolution Time	138
4.3.5. Response Optimisation	141
4.4. Concluding Remarks	144

5.	Evaluation of Innovatively-Formed Enterospheres for Targeted Delivery of Isoniazid	
5.1.	Introduction	146
5.1.1.	Characterisation of Vibrational Transitions by Fourier Transform Infrared Spectroscopy	147
5.1.2.	Characterisation of Degree of Crystallinity by X-Ray Powder Diffraction	148
5.1.3.	Characterisation of Thermal Transitions by Differential Scanning Calorimetry	148
5.1.4.	Characterisation of Cross-link Density by Atomic Absorption Spectroscopy	149
5.1.5.	Mechanisms of Polymer Dissolution and Biodegradation	150
5.2.	Materials and Methods	155
5.2.1.	Materials	155
5.2.2.	Enterosphere Formulations	155
5.2.3.	Characterisation of Vibrational Transitions by Fourier Transform Infrared Spectroscopic Analysis	156
5.2.4.	Characterisation of Degree of Crystallinity by X-Ray Powder Diffraction	156
5.2.5.	Characterisation of Thermal Transitions by Differential Scanning Calorimetry	156
5.2.6.	Characterisation of Cross-linking Cation: MAEA Stoichiometry by Atomic Absorption Spectroscopy	157

5.2.7. Characterisation of Morphological Transitions by Scanning Electron Microscopy	158
5.2.8. Characterisation of Enterosphere Erosion by Gravimetric Transitions	158
5.2.9. Characterisation of Enterosphere Erosion by Volume Reduction	159
5.2.10. Characterisation of Enterosphere Erosion from Drug Release Data	160
5.3. Results and Discussion	160
5.3.1. Vibrational Transitions	160
5.3.2. Degree of Crystallinity	164
5.3.3. Thermal Transitions	172
5.3.4. Cross-linking Cation: MAEA Stoichiometry	176
5.3.5. Morphological Transitions	177
5.3.6. Gravimetric and Volumetric Transitions	180
5.4. Concluding Remarks	185
6. Preliminary Investigation and Characterisation of a Gel-Forming Suspending Agent for Extemporaneous Dispensing	
6.1. Introduction	186
6.2. Preliminary Evaluation of Appropriate Suspending and Gelling Agents for Extemporaneous Dispensing	193
6.2.1. Materials and Methods	193
6.2.1.1. Materials	193
6.2.1.2. Preliminary Suspension Preparation and Evaluation	193
6.2.2. Results and Discussion	194

6.3.	Textural Profiling of a Sodium Starch Glycolate-kappa-Carrageenan Combination: Demonstration of the Functional Synergism	196
6.3.1.	Materials and Methods	196
6.3.1.1.	Materials	196
6.3.1.2.	Preparation of Sodium Starch Glycolate-kappa-Carrageenan Sol and Gel Systems	196
6.3.1.3.	Textural Analysis of Sol and Gel Systems	197
6.3.1.4.	Gelation and Viscosity Analysis of Sol and Gel Systems	198
6.3.1.5.	Statistical Analysis	198
6.3.2.	Results and Discussion	199
6.3.2.1.	Selection of Processing Conditions for Gel Systems	199
6.3.2.2.	Formation of a Three-Dimensional Network in Sol and Gel Systems	199
6.3.2.3.	Textural Analysis of Sol and Gel Systems	202
6.3.2.4.	Viscosity Analysis of Sol and Gel Systems	206
6.4.	Concluding Remarks	208
7.	A Face-Centred Central Composite Design to Optimise the Extemporaneous Use Properties of the Suspension System Delivered as Reconstitutable Multiparticulates	
7.1.	Introduction	210
7.2.	Materials and Methods	212
7.2.1.	Materials	212
7.2.2.	Experimental Design	213
7.2.3.	Evaluation of Granule Flow Properties	214

7.2.3.1. Angle of Repose	214
7.2.3.2. Compressibility Index	215
7.2.4. Evaluation of Extemporaneous Granule Formulations	215
7.2.4.1. Measurement of Sedimentation Volume	215
7.2.4.2. Viscosity Analysis	216
7.2.4.3. Theoretical Sedimentation Rate	217
7.2.4.4. Importance of the Hydrocolloid Stoichiometric Coefficient in Predicting Gel-Formation Time of the Extemporaneous Granules	218
7.3. Results and Discussion	219
7.3.1. Evaluation of Granule Flow Properties	219
7.3.2. Evaluation of Suspensions	219
7.3.3. Response Surface Analysis for Sedimentation Volume Ratio	223
7.3.4. Response Surface Analysis for Final Viscosity	224
7.3.5. Response Surface Analysis for Gelation Rate	225
7.3.6. Response Surface Analysis for Sedimentation Rate	226
7.3.7. Correlation of the Hydrocolloid Stoichiometric Coefficient with Measured Responses for Reconstitutable Granule Formulations	227
7.3.8. Identification of the Optimum Reconstitutable Granule Formulation	228
7.4. Concluding Remarks	229

8. Methodological Approaches for the Simultaneous In Vitro Analysis of Rifampicin and Isoniazid

8.1. Introduction	230
-------------------	-----

8.1.1. Spectrophotometric Analysis of Rifampicin and Isoniazid	232
8.1.2. High Performance Liquid Chromatographic Analysis of Rifampicin and Isoniazid	233
8.2. Materials and Methods	236
8.2.1. Materials – Commercially Available Fixed-Dose Combinations	236
8.2.2. <i>In Vitro</i> Drug Release Testing	236
8.2.3. Quantitative Analytical Determination of Rifampicin and Isoniazid by Regression Analysis of Spectrophotometric Data	237
8.2.4. Quantitative Analytical Determination of Rifampicin and Isoniazid by Colorimetry and High Performance Liquid Chromatography	238
8.3. Results and Discussion	240
8.3.1. Spectrophotometric Analysis	240
8.3.2. Colorimetric and High Performance Liquid Chromatographic Analysis	248
8.4. Concluding Remarks	251
9. Approaches to Formulating Anti-Tuberculosis Nanosystems Embodying A Salted-Out and Cross-linked Architecture	
9.1. Introduction	252
9.2. Materials and Methods	262
9.2.1. Materials	262
9.2.2. Formulation of Nanosystems by Emulsion-Based Salting-Out	263
9.2.3. Formulation of Nanosystems by Aqueous-Based Salting-Out	264
9.2.4. Vibrational Transitions in Nanosystems	266
9.2.5. Elucidation of Particulate Architecture	266

9.2.6. Plackett-Burman Experimental Design for Critical Factor Identification in Nanosystem Manufacture	266
9.2.7. Nanosystem Recovery	268
9.2.8. Determination of Drug Incorporation Efficiency of Nanosystems	268
9.2.9. <i>In Vitro</i> Release Behaviour of Nanosystems	268
9.3. Results and Discussion	269
9.4. Concluding Remarks	279
10. Conclusions and Recommendations	
10.1. Conclusions	280
10.2. Recommendations for Further Development and Implementation of the Anti-Tuberculosis Drug Delivery System	282
References	287

LIST OF FIGURES

	Page
1.1. Estimated TB incidence and mortality	2
1.2. Pathogenesis of TB	5
1.3. Action of anti-TB drugs	8
1.4. Novel anti-TB drug delivery systems	18
1.5. Proposed mechanisms for interaction between RIF and INH	22
1.6. Diagrammatic representation of: (a) the formulation strategy to attain differentiated gastrointestinal delivery in a single dose and (b) the final anti-TB drug delivery system	29
1.7. Organogram of a rational approach to the design of an anti-TB drug delivery system	35
2.1. Candidate enteric polymer	44
2.2. Schematic depicting proposed mechanism for targeted delivery of INH from enterosoluble matrices	51
2.3. Schematic of the film-coating process	54
3.1. Experimental set-up for the air-suspension coating process	65
3.2. Feret's diameters (d_f)	69
3.3. INH calibration curve at 265nm in 0.1M HCl (pH 1.2)	72
3.4. INH calibration curve at 263nm in PBS (pH 6.8)	73
3.5. Stereomicrographs of enterogranules	75
3.6. Feret's diameter of the preliminary enterogranule formulations	75
3.7. Drug release profiles of preliminary enterogranules in acidic media (0.1M HCl, pH 1.2)	75
3.8. Stereomicrographs of representative samples of microenterospheres	81
3.9. Drug release profiles of preliminary microenterosphere formulations in acidic media (0.1M HCl, pH 1.2)	82

3.10.	Schematic of reservoir and multireservoir enterosphere representing double entrapment of INH	84
3.11.	Representative stereomicrographs of representative reservoir enterospheres	87
3.12.	Drug release profiles of reservoir systems in acidic media (0.1M HCl, pH 1.2)	87
3.13.	Schematic of salting-out process for enterosphere fabrication	92
3.14.	Stereomicrographs of representative enterospheres	95
3.15.	Drug release profiles of preliminary enterosphere formulations in acidic media (0.1M HCl, pH 1.2)	100
3.16.	Composite drug release profiles for A7, B8 and R1 representative of the degree of similarity between R1, and the candidate formulation, B8	104
4.1.	Hydration shell of sulphate anions	111
4.2.	Two-dimensional schematic of proposed non-stereo-specific (a) inter- and (b) intra-molecular ionic interactions ('salt-bridges') between the anionic poly(methacrylic acid-co-ethylacrylate) copolymer and cationic agent	111
4.3.	Typical textural profiles for the measurement of (a) deformation energy (upward gradient) and matrix hardness (AUC) and (b) resilience	118
4.4.	Stereomicrographs of enterosphere formulations	120
4.5.	Composite release profiles of the enterosphere formulations in acidic (0.1M HCl, pH 1.2) and phosphate buffered media (pH 6.8)	122
4.6.	Variable resilience of enterosphere formulations in the dry and hydrated state	125
4.7.	Relationship between fractional drug release and acid-hydrated resilience	126
4.8.	3-D scatter plot of matrix hardness vs. molar amount of Zn (n_{Zn}) vs. formulation	127
4.9.	Residual plots	128
4.10.	Interaction plots	134
4.11.	Main effects plots	135
4.12.	Response surface plots	136

4.13.	Stereomicrographs and corresponding scanning electron micrographs of enterosphere formulation 22	139
4.14.	Optimisation plots delineating factor settings and desirability values for optimal formulations	142
4.15.	Composite release profile of INH from optimum formulation	144
5.1.	Relationship between structural variables and properties for the cross-linked enterosphere	146
5.2.	Controlled release of drug molecules from a matrix diffusion-controlled diffusion-type drug delivery device in which solid drug is homogenously dispersed in the polymer matrix	153
5.3.	Proposed interaction between MAEA and INH	162
5.4.	FTIR spectra	163
5.5.	XRPD patterns	167
5.6.	DSC thermograms	168
5.7.	Scanning electron micrographs of DL _{2%} enterospheres	178
5.8.	Scanning electron micrographs of DL _{8%} enterospheres	179
5.9.	Relationship between drug release and erosional transitions (weight and volume)	183
5.10.	Erosional behaviour of representative enterosphere formulations	184
6.1.	Gel formation in carrageenan	190
6.2.	Conical probe configuration illustrating the compression and decompression phases	197
6.3.	(a) Structural formulae of SSG and κ C repeating units and (b) schematic of proposed effect of SSG on κ C due to (A) exclusion effect (B) Coulombic interactions	201
6.4.	Stereomicrographs of SSG- κ C sol systems	201
6.5.	Representative textural profiles depicting the AUC	203
6.6.	Effect of increasing κ C concentrations on compressibility	204

6.7.	Effect of κC levels on the change in viscosity following the sol-gel transition	206
7.1.	Residual plots	221
7.2.	Agreement between experimental and predicted values	222
7.3.	Response surface plot for sedimentation ratio (V/V_0) versus SSG, κC	224
7.4.	Response surface plot for final viscosity versus SSG, κC	225
7.5.	Response surface plot for gelation rate ($\Delta V/\Delta t$) versus SSG, κC	226
7.6.	Response surface plot for sedimentation rate (V) vs SSG, κC	227
8.1.	UV spectra	241
8.2.	PLS analysis of spectrophotometric absorbance data for Rifanah 150	242
8.3.	PLS analysis of spectrophotometric absorbance data for Rifanah 300	243
8.4.	PLS analysis of spectrophotometric absorbance data for optimum RIF-INH dispersible multiparticulate system	244
8.5.	Drug release from FDCs following regression analysis of UV spectrophotometric absorbance data	247
8.6.	Drug release from FDCs following chromatographic determination of INH and colorimetric determination of RIF	250
9.1.	Comparison of complexity as a function of molecular architecture, strategy, quantised building block and technological age highlighting the intricate role of polymers in supramolecular chemistry	254
9.2.	The array of nanosystems encompassed by nanopharmaceuticals	255
9.3.	Fabrication of nanosystems by the emulsion-based salting-out method	261
9.4.	Experimental system set-up for aqueous salting-out by spray atomisation	265
9.5.	SEMs of nanosystems generated by the emulsion-based salting-out approach	270
9.6.	SEMs of nanosystems generated by the aqueous-based salting-out approach	271
9.7.	FTIR spectra of nanosystems	272

9.8.	(a) Schematic of zinc oxide crystal formation and (b) Stereomicrographs depicting tubular morphological transition in NS fabricated by aqueous-based salting-out	274
9.9.	Selected drug release profiles from emulsion-based salted-out nanosystems in PBS (pH 7.0)	275
9.10.	Drug release profiles from aqueous-based salted-out nanosystems in PBS (pH 7.0)	275
9.11.	Surface plots derived from P-B design for emulsion-based nanosystems and aqueous-based nanosystems	276
9.12.	Proposed mechanism for targeted pulmonary delivery of nanosystems via the inhalation route	278
10.1.	Spray-dryer configuration and process staging for enterosphere manufacture	285

LIST OF TABLES

	Page
1.1. Regimen 1 – for treatment of new smear positive adult patients	6
1.2. Classes of anti-TB drugs	9
1.3. Synopsis of novel anti-TB drug delivery systems	10
2.1. Commercially available enteric polymers	40
2.2. Microencapsulation methods for the formulation of enterosoluble multiparticulates	52
2.3. Parameters and process variables affecting solvent evaporation	56
2.4. Common suspending and gelling agents	61
3.1. Identified processing conditions	65
3.2. Formulae for Eudragit S [®] 100 and Eudragit L [®] 100 dispersions	68
3.3. Preliminary enterogranule formulations	69
3.4. Accuracy determination for INH assay method in 0.1M HCl	73
3.5. Precision determination for INH assay method in 0.1M HCl	73
3.6. Accuracy determination for INH assay method in 0.2M PBS pH 6.8	74
3.7. Precision determination for INH assay method in 0.2M PBS pH 6.8	74
3.8. Preliminary microenterosphere formulations	78
3.9. Particle size, entrapment and release characteristics of preliminary microenterosphere formulations	81
3.10. Solubility and key hydrational properties of electrolytes tested	93
3.11. Preliminary enterosphere formulations	93
3.12. Particle size, entrapment and release characteristics of preliminary enterosphere formulations	96
3.13. Similarity and difference factors of the preliminary enterosoluble formulations	104

4.1.	Factors and levels of independent variables generated by the 3 ⁴ Box- Behnken Design	114
4.2.	Textural parameters for determination of matrix hardness, deformation energy and matrix resilience	118
4.3.	Measured responses for the enterosphere formulations	123
4.4.	Measured textural properties of the experimentally synthesised variants	124
4.5.	Correlation between experimental and predicted values for n _{Zn} , DEE, and MDT	130
4.6.	Estimated p-values for the measured responses	131
4.7.	Constrained settings for response optimisation	142
4.8.	Experimental and predicted response values for the optimised formulations	143
5.1.	Band assignments for MAEA-INH physical mixture	161
5.2.	Intensity counts of representative samples at the main interplanar distances	166
5.3.	Thermodynamically-derived data for enterosphere formulations with relation to cross-linking cation: MAEA stoichiometry	175
6.1.	Characteristics of hydrophilic suspending agents for extemporaneous dispensing	195
6.2.	<i>TA-Xt.plus</i> settings for sol and gel analysis.	198
6.3.	Textural properties and viscosity of SSG-κC Systems	204
7.1.	Suspending Agents and Levels Derived from the Central Composite Design	213
7.2.	Results from analysis of suspension formulations	219
7.3.	Estimated regression coefficients and p-values for sedimentation ratio (V/V ₀), final viscosity, gelation rate (ΔV/Δt) and sedimentation rate (V)	222
7.4.	Constraints for optimal suspension formulation	228
7.5.	Experimental and predicted response values for the optimised gelling suspension	228

8.1.	Specifications for HPLC methodologies	235
8.2.	Gradient program prescribed in the USP method	235
8.3.	Drug content validation in FDC tablet formulations	245
8.4.	Model selection and validation and regression coefficients for RIF release prediction	245
8.5.	Model selection and validation and regression coefficients for INH release prediction	245
9.1.	Compositions of preliminary formulations for production of nanosystems by the emulsion-based salting-out approach	263
9.2.	Compositions of preliminary formulations for production of nanosystems by novel aqueous-based salting-out approach	265
9.3.	Plackett-Burman design for emulsion-based salted-out nanosystems	267
9.4.	Plackett-Burman design for aqueous-based salted-out nanosystems	267
9.5.	Measured yield and DIE responses for Plackett-Burman generated formulations	274